EWA
VRDN icon

EverSource Wealth Advisors’s Viridian Therapeutics VRDN Stock Holding History

EverSource Wealth Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.1K Buy
223
+103
+86% +$1.66K ﹤0.01% 3382
2026
Q1 		$2.35K Buy
120
+30
+33% +$891 ﹤0.01% 3590
2025
Q4 		$2.8K Sell
90
-2
-2% -$55 ﹤0.01% 3369
2025
Q3 		$1.99K Buy
92
+43
+88% +$776 ﹤0.01% 3514
2025
Q2 		$685 Buy
49
+29
+145% +$394 ﹤0.01% 3821
2025
Q1 		$270 Buy
20
+14
+233% +$238 ﹤0.01% 3626
2024
Q4 		$115 Buy
+6
New +$130 ﹤0.01% 3521

Other funds holding VRDN

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

EverSource Wealth Advisors's VRDN Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Viridian Therapeutics (VRDN) stake by 86% in Q2 2026, buying an estimated $1.66K and bringing the position to 223 shares worth $4.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3382.

EverSource Wealth Advisors first reported a position in VRDN in Q4 2024 and has held it in 7 quarters since. 40 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • EverSource Wealth Advisors held 223 shares of Viridian Therapeutics worth $4.1K as of Q2 2026.
  • EverSource Wealth Advisors bought 103 Viridian Therapeutics shares in Q2 2026, an estimated $1.66K.
  • Viridian Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3382 holding.
  • EverSource Wealth Advisors first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 40 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.